Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2013 1
2014 6
2015 11
2016 9
2017 21
2018 37
2019 64
2020 73
2021 97
2022 136
2023 118
2024 117
2025 115
2026 57

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

796 results

Results by year

Citations

4 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention.
Caronna E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P. Caronna E, et al. Handb Clin Neurol. 2024;199:107-124. doi: 10.1016/B978-0-12-823357-3.00024-0. Handb Clin Neurol. 2024. PMID: 38307640 Review.
In the last years, two classes of drugs antagonizing CGRP have therefore been developed as the first migraine-specific preventive treatments: anti-CGRP monoclonal antibodies (mAbs) and gepants. ...In this review, we provide an overview of …
In the last years, two classes of drugs antagonizing CGRP have therefore been developed as the first migraine-specific prev …
Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.
Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC. Messina R, et al. Cephalalgia. 2023 Mar;43(3):3331024231152169. doi: 10.1177/03331024231152169. Cephalalgia. 2023. PMID: 36786548 Free article.
This study aimed to compare the safety and tolerability of anti-calcitonin gene-related peptide monoclonal antibodies and gepants in migraine prevention. METHODS: A network meta-analysis of phase 3 randomized controlled trials assessing the safety and …
This study aimed to compare the safety and tolerability of anti-calcitonin gene-related peptide monoclonal antibodies and gepa …
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world.
Caronna E, Gallardo VJ, Egeo G, Vázquez MM, Castellanos CN, Membrilla JA, Vaghi G, Rodríguez-Montolio J, Fabregat Fabra N, Sánchez-Caballero F, Jaimes Sánchez A, Muñoz-Vendrell A, Oliveira R, Gárate G, González-Osorio Y, Guisado-Alonso D, Ornello R, Thunstedt C, Fernández-Lázaro I, Torres-Ferrús M, Alpuente A, Torelli P, Aurilia C, Pére RL, Castrillo MJR, Icco R, Sances G, Broadhurst S, Ong HC, García AG, Campoy S, Sanahuja J, Cabral G, Beltrán Blasco I, Waliszewska-Prosół M, Pereira L, Layos-Romero A, Luzeiro I, Dorado L, Álvarez Escudero MR, May A, López-Bravo A, Martins IP, Sundal C, Irimia P, Lozano Ros A, Gago-Veiga AB, Juanes FV, Ruscheweyh R, Sacco S, Cuadrado-Godia E, García-Azorín D, Pascual J, Gil-Gouveia R, Huerta-Villanueva M, Rodriguez-Vico J, Viguera Romero J, Obach V, Santos-Lasaosa S, Ghadiri-Sani M, Tassorelli C, Díaz-de-Terán J, Díaz Insa S, Oria CG, Barbanti P, Pozo-Rosich P; EUREkA study group. Caronna E, et al. J Neurol Neurosurg Psychiatry. 2024 Sep 17;95(10):927-937. doi: 10.1136/jnnp-2023-333295. J Neurol Neurosurg Psychiatry. 2024. PMID: 38777579
BACKGROUND: Anti-CGRP monoclonal antibodies (anti-CGRP MAbs) are approved and available treatments for migraine prevention. ...CONCLUSIONS: This is the largest real-world study of migraine patients treated with anti-CGRP MAb …
BACKGROUND: Anti-CGRP monoclonal antibodies (anti-CGRP MAbs) are approved and available treatments for migrai …
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update.
Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, Katsarava Z, MaassenVanDenBrink A, Martelletti P, Mitsikostas DD, Ornello R, Reuter U, Sanchez-Del-Rio M, Sinclair AJ, Terwindt G, Uluduz D, Versijpt J, Lampl C. Sacco S, et al. J Headache Pain. 2022 Jun 11;23(1):67. doi: 10.1186/s10194-022-01431-x. J Headache Pain. 2022. PMID: 35690723 Free PMC article.
BACKGROUND: A previous European Headache Federation (EHF) guideline addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway to prevent migraine. ...Nevertheless, we provided updated suggestions reg …
BACKGROUND: A previous European Headache Federation (EHF) guideline addressed the use of monoclonal antibodies targeting the c …
CGRP as the target of new migraine therapies - successful translation from bench to clinic.
Edvinsson L, Haanes KA, Warfvinge K, Krause DN. Edvinsson L, et al. Nat Rev Neurol. 2018 Jun;14(6):338-350. doi: 10.1038/s41582-018-0003-1. Nat Rev Neurol. 2018. PMID: 29691490 Free article. Review.
CGRP receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (eptinezumab, fremanezumab and galcanezumab) or the CGRP receptor (erenumab) effectively preve …
CGRP receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal …
Migraine.
Ferrari MD, Goadsby PJ, Burstein R, Kurth T, Ayata C, Charles A, Ashina M, van den Maagdenberg AMJM, Dodick DW. Ferrari MD, et al. Nat Rev Dis Primers. 2022 Jan 13;8(1):2. doi: 10.1038/s41572-021-00328-4. Nat Rev Dis Primers. 2022. PMID: 35027572 Review.
Intramuscular onabotulinumtoxinA may be helpful in chronic migraine (migraine on 15 days per month) and monoclonal antibodies targeting CGRP or its receptor, as well as two gepants, have proven effective and well tolerated for the preventive …
Intramuscular onabotulinumtoxinA may be helpful in chronic migraine (migraine on 15 days per month) and monoclonal …
Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update.
Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A; American Headache Society. Charles AC, et al. Headache. 2024 Apr;64(4):333-341. doi: 10.1111/head.14692. Epub 2024 Mar 11. Headache. 2024. PMID: 38466028
RESULTS: The evidence for the efficacy, tolerability, and safety of CGRP-targeting migraine preventive therapies (the monoclonal antibodies: erenumab, fremanezumab, galcanezumab, and eptinezumab, and the gepants: rimegepant and atogepant) is sub …
RESULTS: The evidence for the efficacy, tolerability, and safety of CGRP-targeting migraine preventive therapies (the …
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.
Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. Ailani J, et al. Headache. 2021 Jul;61(7):1021-1039. doi: 10.1111/head.14153. Epub 2021 Jun 23. Headache. 2021. PMID: 34160823
OBJECTIVE: To incorporate recent research findings, expert consensus, and patient perspectives into updated guidance on the use of new acute and preventive treatments for migraine in adults. BACKGROUND: The American Headache Society previously published a Consensus …
OBJECTIVE: To incorporate recent research findings, expert consensus, and patient perspectives into updated guidance on the use of new acute …
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention.
Lampl C, Seng E, Vincent M, Lenderking WR, Hoyt M, Hetherington L, Ladd MK, Malley K, Chen J, Viktrup L. Lampl C, et al. J Headache Pain. 2024 Dec 18;25(1):220. doi: 10.1186/s10194-024-01927-8. J Headache Pain. 2024. PMID: 39695402 Free PMC article.
METHODS: A cross-sectional online survey was conducted with participants aged 18 years, 250 with episodic migraine (EM) and 250 with chronic migraine (CM), having 4 monthly migraine headache days. ...Migraine family history was reported in 59% of p …
METHODS: A cross-sectional online survey was conducted with participants aged 18 years, 250 with episodic migraine (EM) and 250 wit …
Botulinum Toxin in the Treatment of Headache.
Becker WJ. Becker WJ. Toxins (Basel). 2020 Dec 17;12(12):803. doi: 10.3390/toxins12120803. Toxins (Basel). 2020. PMID: 33348571 Free PMC article. Review.
Ongoing research is gradually shedding light on its mechanism of action in migraine prevention. Given that its mechanism of action is quite different from that of the new monoclonal antibodies directed against calcitonin gene-related peptide (CGRP …
Ongoing research is gradually shedding light on its mechanism of action in migraine prevention. Given that its mechanism of ac …
796 results